Проблема безопасности липидснижающей терапии
https://doi.org/10.18087/cardio.2505
Аннотация
Настоящая работа посвящена анализу современных публикаций, оценивающих безопасность липидснижающей терапии. Поиск литературы был проведен на сайтах кардиологических обществ, а также по онлайновым базам данных PubMed, EMBASE, eLibrary с использованием ключевых слов: статины, непереносимость статинов, липидснижающая терапия, статины и безопасность, statins, statin intolerance, lipid lowering therapy, statin safety, statin аdverse effects. Основное внимание уделено именно статинам, так как они считаются самыми назначаемыми, высокоэффективными и безопасными препаратами при первичной и вторичной кардиоваскулярной профилактике. В данном литературном обзоре последовательно изложена информация о миопатиях, печеночной и почечной дисфункции, потенцировании СД, а также о ряде других возможных неблагоприятных эффектов липидснижающей терапии. Автором сделан вывод, что несмотря на высокую безопасность статинов, признанную всеми кардиологическими сообществами мира, практикующие врачи все же продолжают необоснованно отменять статины, подвергая больного еще большей опасности.
Ключевые слова
Список литературы
1. Бойцов С.А., Погосова Н.В., Бубнова М.Г., Драпкина О.М., Гаврилова Н.Е., Еганян Р.А. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;23(6):7–122. DOI: 10.15829/1560-4071-2018-6-7-122
2. Stevens W, Peneva D, Li JZ, Liu LZ, Liu G, Gao R et al. Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China. BMC Health Services Research. 2016;16(1):175. DOI: 10.1186/s12913-016-1420-8
3. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37(39):2999–3058. DOI: 10.1093/eurheartj/ehw272
4. Ежов М.В., Сергиенко И.В., Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., Бажан С.С. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017;3:5-22
5. Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of Clinical Lipidology. 2015;9(6):S1-S122.e1. DOI: 10.1016/j.jacl.2015.09.002
6. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K et al. Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science. 2015;11(1):1–23. DOI: 10.5114/aoms.2015.49807
7. Sposito AC, Faria Neto JR, Carvalho LSF de, Lorenzatti A, Cafferata A, Elikir G et al. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Current Medical Research and Opinion. 2017;33(2):239–51. DOI: 10.1080/03007995.2016.1252740
8. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7. PMID: 12132976
9. Шальнова С.А., Деев А.Д., Метельская В.А., Евстифеева С.Е., Ротарь О.П., Жернакова Ю.В. и др. Информированность и особенности терапии статинами у лиц с различным сердечно-сосудистым риском: исследование ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2016;15(4):29-37. DOI: 10.15829/1728-8800-2016-4-29-37
10. Марцевич С.Ю., Лерман О.В., Кутишенко Н.П., Суворов А.Ю. Проблема назначения статинов больным с сердечнососудистыми заболеваниями и сопутствующими болезнями печени. Что о ней думают практические врачи? Рациональная фармакотерапия в кардиологии. 2015;11(2):167-9
11. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. European Heart Journal. 2013;34(38):2940–8. DOI: 10.1093/eurheartj/eht295
12. Knyazeva Yu.S. Preferences and awareness of therapists and cardiologists in the appointment of hypolipidemic drugs. Proceedings of Voronezh State University. Series: Chemistry. Biology. Pharmacy. 2017;2:124– 7. [Rusian: Князева Ю.С. Предпочтения и информированность врачей-терапевтов и врачей-кардиологов при назначении гиполипидемических лекарственных препаратов. Вестник ВГУ. Серия: Химия. Биология. Фармация. 2017;2:124-7]
13. Документационный центр ВОЗ: Информационный бюллетень «Доступность лекарственных препаратов и их рациональное использование». 2013;1–9. Доступно на: http://whodc.mednet.ru/en/component/attachments/download/96.html
14. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL–C and non-HDL–C: Results from the VOYAGER meta-analysis. European Journal of Preventive Cardiology. 2016;23(7):744–7. DOI: 10.1177/2047487315598710
15. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin ( JUPITER) Trial. Circulation: Cardiovascular Genetics. 2012;5(2):257–64. DOI: 10.1161/CIRCGENETICS.111.961144
16. Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. International Journal of Cardiology. 2012;159(3):169–76. DOI: 10.1016/j.ijcard.2011.07.048
17. Ose L. Pitavastatin: a distinctive lipid-lowering drug. Clinical Lipidology. 2010;5(3):309–23. DOI: 10.2217/clp.10.28
18. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal. 2015;36(17):1012– 22. DOI: 10.1093/eurheartj/ehv043
19. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. Journal of Clinical Lipidology. 2012;6(3):208–15. DOI: 10.1016/j.jacl.2012.03.003
20. Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: A population-based retrospective cohort study in Israel. Clinical Therapeutics. 2008;30(11):2167–79. DOI: 10.1016/j. clinthera.2008.11.012
21. Vrablik M, Zlatohlavek L, Stulc T, Adamkova V, Prusikova M, Schwarzova L et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiological Research. 2014;63 Suppl 3:S327-334. PMID: 25428737
22. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the Statin Muscle Safety Task Force: 2014 update. Journal of Clinical Lipidology. 2014;8(3):S58–71. DOI: 10.1016/j.jacl.2014.03.004
23. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J et al. Effect of Statins on Skeletal Muscle Function. Circulation. 2013;127(1):96– 103. DOI: 10.1161/CIRCULATIONAHA.112.136101
24. Mancini GBJ, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J et al. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Canadian Journal of Cardiology. 2016;32(7):S35–65. DOI: 10.1016/j.cjca.2016.01.003
25. Lim S, Despres J-P, Koh KK. Prevention of Atherosclerosis in Overweight/Obese Patients. Circulation Journal. 2011;75(5):1019–27. DOI: 10.1253/circj.CJ-10-1240
26. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis: Current Opinion in Lipidology. 2007;18(4):401–8. DOI: 10.1097/MOL.0b013e32825a6773
27. Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions with Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016;134(21):e468–95. DOI: 10.1161/CIR.0000000000000456
28. Naci H, Brugts J, Ades T. Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials. Circulation: Cardiovascular Quality and Outcomes. 2013;6(4):390–9. DOI: 10.1161/CIRCOUTCOMES.111.000071
29. Phan K, Gomez Y-H, Elbaz L, Daskalopoulou SS. Statin treatment nonadherence and discontinuation: clinical implications and potential solutions. Current Pharmaceutical Design. 2014;20(40):6314–24. PMID: 24953391
30. Haukka J, Niskanen L, Partonen T, Lönnqvist J, Tiihonen J. Statin usage and all-cause and disease-specific mortality in a nationwide study: STATINS AND MORTALITY. Pharmacoepidemiology and Drug Safety. 2012;21(1):61–9. DOI: 10.1002/pds.2255
31. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M et al. Discontinuation of Statins in Routine Care Settings: A Cohort Study. Annals of Internal Medicine. 2013;158(7):526–34. DOI: 10.7326/0003-4819158-7-201304020-00004
32. Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL et al. Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. American Heart Journal. 2013;166(3):597–603. DOI: 10.1016/j.ahj.2013.06.004
33. Keating AJ, Campbell KB, Guyton JR. Intermittent Nondaily Dosing Strategies in Patients with Previous Statin-Induced Myopathy. Annals of Pharmacotherapy. 2013;47(3):398–404. DOI: 10.1345/aph.1R509
34. Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-Week Rosuvastatin (2.5 to 20 mg) in Patients with a Previous Statin Intolerance. The American Journal of Cardiology. 2009;103(3):393–4. DOI: 10.1016/j. amjcard.2008.09.095
35. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of Ezetimibe Alone or in Combination with Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients. The American Journal of Cardiology. 2008;101(4):483–5. DOI: 10.1016/j.amjcard.2007.09.096
36. Jacobson TA. Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia. Mayo Clinic Proceedings. 2008;83(6):687–700. DOI: 10.4065/83.6.687
37. Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z et al. Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients with a History of Muscle-Related Side Effects With Other Statins. The American Journal of Cardiology. 2008;101(4):490–6. DOI: 10.1016/j. amjcard.2007.09.099
38. Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. European Heart Journal. 2013;34(24):1783–9. DOI: 10.1093/eurheartj/eht088
39. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for Hypercholesterolemia. Annual Review of Pharmacology and Toxicology. 2014;54(1):273–93. DOI: 10.1146/annurev-pharmtox-011613-140025
40. Qian LJ, Gao Y, Zhang YM, Chu M, Yao J, Xu D. Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. Scientific Reports. 2017;7(1):238. DOI: 10.1038/s41598-017-00316-3
41. Tavori H, Melone M, Rashid S. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Expert Review of Cardiovascular Therapy. 2014;12(10):1137–44. DOI: 10.1586/14779072.2014.954551
42. Guo J, Meng F, Ma N, Li C, Ding Z, Wang H et al. Meta-Analysis of Safety of the Coadministration of Statin with Fenofibrate in Patients With Combined Hyperlipidemia. The American Journal of Cardiology. 2012;110(9):1296–301. DOI: 10.1016/j.amjcard.2012.06.050
43. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDLCholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology. 2017;70(14):1785–822. DOI: 10.1016/j.jacc.2017.07.745
44. Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed Statin Myopathy. Atherosclerosis. 2015;238(2):329–35. DOI: 10.1016/j.atherosclerosis.2014.12.016
45. Pfeifer M, Begerow B, Minne HW. Vitamin D and Muscle Function. Osteoporosis International. 2002;13(3):187–94. DOI: 10.1007/s001980200012
46. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 patients. International Journal of Cardiology. 2015;178:111–6. DOI: 10.1016/j.ijcard.2014.10.118
47. Antman EM, Jessup M. Clinical Practice Guidelines for Chronic Cardiovascular Disorders: A Roadmap for the Future. JAMA. 2014;311(12):1195. DOI: 10.1001/jama.2014.1742
48. Сусеков А.В. Гиполипидемическая терапия: взгляд в прошлое и перспективы на ближайшее будущее. Кардиология. 2016;56(6):81-8. DOI: 10.18565/cardio.2016.6.81-88
49. Russo M, Scobey M, Bonkovsky H. Drug-Induced Liver Injury Associated with Statins. Seminars in Liver Disease. 2009;29(04):412–22. DOI: 10.1055/s-0029-1240010
50. Fitchett DH, Hegele RA, Verma S. Cardiology patient page. Statin Intolerance. Circulation. 2015;131(13):e389-91. DOI: 10.1161/CIRCULATIONAHA.114.013189
51. Björnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver International. 2017;37(2):173–8. DOI: 10.1111/liv.13308
52. Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE et al. Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network. Hepatology. 2014;60(2):679–86. DOI: 10.1002/hep.27157
53. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. Journal of Hepatology. 2012;56(2):374–80. DOI: 10.1016/j.jhep.2011.07.023
54. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. The American Journal of Medicine. 2005;118(6):618–24. DOI: 10.1016/j.amjmed.2005.02.008
55. Karahalil B, Hare E, Koç G, Uslu İ, Şentürk K, Özkan Y. Hepatotoxicity associated with statins. Archives of Industrial Hygiene and Toxicology. 2017;68(4):254–60. DOI: 10.1515/aiht-2017-68-2994
56. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM: An International Journal of Medicine. 2012;105(2):145–57. DOI: 10.1093/qjmed/hcr158
57. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197–c2197. DOI: 10.1136/bmj. c2197
58. Clarke AT, Johnson PCD, Hall GC, Ford I, Mills PR. High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort. PLOS ONE. 2016;11(3):e0151587. DOI: 10.1371/journal.pone.0151587
59. Center for Drug Evaluation and Research. Drug Safety and Availability FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. [Internet] 2012. Available at: https://www. fda.gov/Drugs/DrugSafety/ucm293101.htm
60. Marrone G, Vaccaro FG, Biolato M, Miele L, Liguori A, Araneo C et al. Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind. European Review for Medical and Pharmacological Sciences. 2017;21(1 Suppl):122–34. PMID: 28379587
61. Bays H, Cohen DE, Chalasani N, Harrison SA. An assessment by the Statin Liver Safety Task Force: 2014 update. Journal of Clinical Lipidology. 2014;8(3):S47–57. DOI: 10.1016/j.jacl.2014.02.011
62. Бельдиев С.Н. Проблема назначения статинов больным с сердечно-сосудистыми заболеваниями и сопутствующими болезнями печени. Что препятствует преодолению статинофобии? Рациональная фармакотерапия в кардиологии. 2016;12(3):325-30. DOI: 10.20996/1819-6446-2016-12-3-325-330
63. Bergland Ellingsen S, Nordmo E, Tore Lappegård K. Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination with Ezetimibe. Clinical Medicine Insights: Case Reports. 2017;10:117954761773137. DOI: 10.1177/1179547617731375
64. Ritchie SR, Orr DW, Black PN. Severe jaundice following treatment with ezetimibe: European Journal of Gastroenterology & Hepatology. 2008;20(6):572–3. DOI: 10.1097/MEG.0b013e3282f1752d
65. Castellote J, Ariza J, Rota R, Girbau A, Xiol X. Serious drug-induced liver disease secondary to ezetimibe. World Journal of Gastroenterology. 2008;14(32):5098–9. DOI: 10.3748/wjg.14.5098
66. Culver AL. Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women’s Health Initiative. Archives of Internal Medicine. 2012;172(2):144–52. DOI: 10.1001/archinternmed.2011.625
67. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet. 2010;375(9716):735–42. DOI: 10.1016/S0140-6736(09)61965-6
68. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. The Lancet. 2012;380(9841):565– 71. DOI: 10.1016/S0140-6736(12)61190-8
69. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin Therapy and Risk of Developing Type 2 Diabetes: A MetaAnalysis. Diabetes Care. 2009;32(10):1924–9. DOI: 10.2337/dc09-0738
70. Marathe PH, Gao HX, Close KL. American Diabetes Association Standards of Medical Care in Diabetes 2017. Journal of Diabetes. 2017;9(4):320–4. DOI: 10.1111/1753-0407.12524
71. Authors/Task Force Members, Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal. 2013;34(39):3035–87. DOI: 10.1093/eurheartj/eht108
72. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26(10):2713–21. PMID: 14514569
73. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357–62. PMID: 11157685
74. Huang C-H, Huang Y-Y, Hsu BR-S. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. Journal of Diabetes Investigation. 2016;7(5):769–76. DOI: 10.1111/jdi.12483
75. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 2008;359(21):2195–207. DOI: 10.1056/NEJMoa0807646
76. Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun C-C et al. Predictors of New-Onset Diabetes in Patients Treated with Atorvastatin. Journal of the American College of Cardiology. 2011;57(14):1535–45. DOI: 10.1016/j.jacc.2010.10.047
77. Abbas A, Milles J, Ramachandran S. Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia. Clinical Medicine Insights: Endocrinology and Diabetes. 2012;5:CMED.S7591. DOI: 10.4137/CMED.S7591
78. Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T et al. Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. The American Journal of Cardiology. 2013;111(8):1123–30. DOI: 10.1016/j.amjcard.2012.12.037
79. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346(may23 4):f2610–f2610. DOI: 10.1136/bmj.f2610
80. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population: Statins and risk of treated incident diabetes. British Journal of Clinical Pharmacology. 2013;75(4):1118–24. DOI: 10.1111/j.1365-2125.2012.04403.x
81. Ma T, Tien L, Fang C-L, Liou Y-S, Jong G-P. Statins and New-Onset Diabetes: A Retrospective Longitudinal Cohort Study. Clinical Therapeutics. 2012;34(9):1977–83. DOI: 10.1016/j.clinthera.2012.08.004
82. Olotu BS, Shepherd MD, Novak S, Lawson KA, Wilson JP, Richards KM et al. Use of Statins and the Risk of Incident Diabetes: A Retrospective Cohort Study. American Journal of Cardiovascular Drugs. 2016;16(5):377– 90. DOI: 10.1007/s40256-016-0176-1
83. Casula M, Mozzanica F, Scotti L, Tragni E, Pirillo A, Corrao G et al. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutrition, Metabolism and Cardiovascular Diseases. 2017;27(5):396–406. DOI: 10.1016/j.numecd.2017.03.001
84. Preiss D. Risk of Incident Diabetes with Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis. JAMA. 2011;305(24):2556–64. DOI: 10.1001/jama.2011.860
85. Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M et al. The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atherosclerosis Supplements. 2014;15(1):1–15. DOI: 10.1016/j.atherosclerosissup.2014.04.001
86. Моисеев В.С., Мухин Н.А., Смирнов А. В., Кобалава Ж.Д., Бобкова И.Н., Виллевальде С.В. и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Российский кардиологический журнал. 2014;19(8):7-37. DOI: 10.15829/1560-4071-2014-8-7-37
87. Зыков М.В., Кашталап В.В., Шафранская К.С., Быкова И.С., Калаева В.В., Каретникова В.Н. и др. Связь различных факторов кардиоваскулярного риска с нарушением функции почек у больных острым коронарным. Кардиологический вестник. 2016;11(1):38-42
88. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen M-R, Wiklund O et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3–46. PMID: 21882396
89. Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: why, who and when? Expert Opinion on Pharmacotherapy. 2010;11(16):2665–74. DOI: 10.1517/14656566.2010.512419
90. Wong MG, Wanner C, Knight J, Perkovic V. Lowering cholesterol in chronic kidney disease: is it safe and effective? European Heart Journal. 2015;36(43):2988–95. DOI: 10.1093/eurheartj/ehv393
91. Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. The Lancet Diabetes & Endocrinology. 2016;4(10):829–39. DOI: 10.1016/S2213-8587(16)30156-5
92. Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: who benefits? QJM: An International Journal of Medicine. 2017;110(8):493–500. DOI: 10.1093/qjmed/hcx040
93. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S49–73. DOI: 10.1161/01.cir.0000437741.48606.98
94. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of the American College of Cardiology. 2014;63(25):2889–934. DOI: 10.1016/j.jacc.2013.11.002
95. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. Journal of Clinical Lipidology. 2015;9(2):129–69. DOI: 10.1016/j.jacl.2015.02.003
96. Kosmas CE, DeJesus E, Sourla E, Morcelo R, Montan PD, Guzman E. Effects of Statins on Cardiovascular Outcomes in Patients with Chronic Kidney Disease. Clinical Medicine Insights: Therapeutics. 2017;9:1179559X1771902. DOI: 10.1177/1179559X17719029
97. Zhang Z, Wu P, Zhang J, Wang S, Zhang G. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A metaanalysis. Pharmacological Research. 2016;105:74–83. DOI: 10.1016/j. phrs.2016.01.005
98. Su X, Zhang L, Lv J, Wang J, Hou W, Xie X et al. Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases. 2016;67(6):881–92. DOI: 10.1053/j.ajkd.2016.01.016
99. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews. 2014;31(5):CD007784. DOI: 10.1002/14651858.CD007784.pub2
100. Sanguankeo A, Upala S, Cheungpasitporn W, Ungprasert P, Knight EL. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. PLOS ONE. 2015;10(7):e0132970. DOI: 10.1371/journal.pone.0132970
101. Shen X, Zhang Z, Zhang X, Zhao J, Zhou X, Xu Q et al. Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. Lipids in Health and Disease. 2016;15(1):179. DOI: 10.1186/s12944-016-0350-0
102. Han E, Kim G, Lee J-Y, Lee Y, Kim BS, Lee B-W et al. Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes. Endocrinology and Metabolism. 2017;32(2):274. DOI: 10.3803/EnM.2017.32.2.274
103. Savarese G, Musella F, Volpe M, Paneni F, Perrone-Filardi P. Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis. International Journal of Cardiology. 2013;167(6):2482–9. DOI: 10.1016/j.ijcard.2012.05.010
104. Wu Y, Wang Y, An C, Dong Z, Liu H, Zhang Y et al. Effects of rosuvastatin and atorvastatin on renal function: meta-analysis. Circulation Journal: Official Journal of the Japanese Circulation Society. 2012;76(5):1259–66. PMID: 22382383
105. De Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJL, Molitoris BA et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes & Endocrinology. 2015;3(3):181–90. DOI: 10.1016/S2213-8587(14)70246-3
106. Rutter MK, Prais HR, Charlton-Menys V, Gittins M, Roberts C, Davies RR et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of highvs. low-dose atorvastatin 1: Atorvastatin dose and diabetic nephropathy. Diabetic Medicine. 2011;28(1):100–8. DOI: 10.1111/j.14645491.2010.03139.x
107. Lai C-L, Chou H-W, Chan KA, Lai M-S. Effects of Atorvastatin and Rosuvastatin on Renal Function in Patients with Type 2 Diabetes Mellitus. The American Journal of Cardiology. 2015;115(5):619–24. DOI: 10.1016/j.amjcard.2014.12.009
108. Kimura S, Inoguchi T, Yokomizo H, Maeda Y, Sonoda N, Takayanagi R. Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes, Obesity and Metabolism. 2012;14(7):666–9. DOI: 10.1111/j.1463-1326.2012.01566.x
109. Honore PM, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, De Regt J et al. Statins and the Kidney: Friend or Foe? Blood Purification. 2017;43(1–3):91–6. DOI: 10.1159/000453577
110. Kolh P, Windecker S, Alfonso F, Collet J-P, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery. 2014;46(4):517–92. DOI: 10.1093/ejcts/ezu366
111. Барбараш О.Л., Малева О.В., Трубникова О.А. Эффективность и безопасность статинов в кардиохирургии. Доктор.ру. 2016;2(119):12-7
112. He S, Liu Q, Li H, Tian F, Chen S, Weng J. Role of statins in preventing cardiac surgery-associated acute kidney injury: an updated meta-analysis of randomized controlled trials. Therapeutics and Clinical Risk Management. 2018;Volume 14:475–82. DOI: 10.2147/TCRM.S160298
113. McWilliam SJ, Antoine DJ, Pirmohamed M. Repurposing Statins for Renal Protection: Is It a Class Effect? Repurposing Statins for Renal Protection. Clinical and Translational Science. 2018;11(2):100–2. DOI: 10.1111/cts.12521
114. Xiong B, Nie D, Cao Y, Zou Y, Yao Y, Qian J et al. Preoperative Statin Treatment for the Prevention of Acute Kidney Injury in Patients Undergoing Cardiac Surgery: A Meta-Analysis of Randomised Controlled Trials. Heart, Lung and Circulation. 2017;26(11):1200–7. DOI: 10.1016/j. hlc.2016.11.024
115. Zhen-Han L, Rui S, Dan C, Xiao-Li Z, Qing-Chen W, Bo F. Perioperative statin administration with decreased risk of postoperative atrial fibrillation, but not acute kidney injury or myocardial infarction: A meta-analysis. Scientific Reports. 2017;7(1):10091. DOI: 10.1038/s41598-017-10600-x
116. Liu Y, Liu Y, Tan N, Chen J, Zhou Y, Li L et al. Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. PLoS ONE. 2014;9(10):e111124. DOI: 10.1371/journal.pone.0111124
117. Wang X, Zhang T, Hu L, Sun S, Zhang W, Sun Z et al. Comparison of Effects of Different Statins on Contrast-Induced Acute Kidney Injury in Rats: Histopathological and Biochemical Findings. Oxidative Medicine and Cellular Longevity. 2017;2017(2017):6282486. DOI: 10.1155/2017/6282486
118. Acharya T, Huang J, Tringali S, Frei CR, Mortensen EM, Mansi IA. Statin Use and the Risk of Kidney Disease with Long-Term Follow-Up (8.4-Year Study). The American Journal of Cardiology. 2016;117(4):647–55. DOI: 10.1016/j.amjcard.2015.11.031
119. Corrao G, Soranna D, Casula M, Merlino L, Porcellini MG, Catapano AL. High-potency statins increase the risk of acute kidney injury: Evidence from a large population-based study. Atherosclerosis. 2014;234(1):224– 9. DOI: 10.1016/j.atherosclerosis.2014.02.022
120. Chung Y-H, Lee Y-C, Chang C-H, Lin M-S, Lin J-W, Lai M-S. Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure: statins and renal failure. Pharmacoepidemiology and Drug Safety. 2013;22(6):583–92. DOI: 10.1002/pds.3433
121. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ. 2013;346(mar18 3):f880–f880. DOI: 10.1136/bmj.f880
122. Sarnak MJ, Bloom R, Muntner P, Rahman M, Saland JM, Wilson PWF et al. KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. American Journal of Kidney Diseases. 2015;65(3):354–66. DOI: 10.1053/j.ajkd.2014.10.005
123. Оганов Р.Г., Денисов И.Н., Симаненков В.И., Бакулин И.Г., Бакулина Н.В., Болдуева С.А. и др. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2017;16(6):5-56. DOI: 10.15829/1728-8800-2017-6-5-56
124. Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Current Drug Metabolism. 2010;11(8):678–85. PMID: 20973757
125. Goh IXW, How CH, Tavintharan S. Cytochrome P450 drug interactions with statin therapy. Singapore Medical Journal. 2013;54(3):131– 5. PMID: 23546024
126. Ramkumar S, Raghunath A, Raghunath S. Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiologica Sinica. 2016;32(6):631–9. PMID: 27899849
127. Spence JD, Dresser GK. Overcoming Challenges with Statin Therapy. Journal of the American Heart Association. 2016;5(1):e002497. DOI: 10.1161/JAHA.115.002497
128. Bitzur R. Remembering Statins: Do Statins Have Adverse Cognitive Effects? Diabetes Care. 2016;39(Supplement 2):S253–9. DOI: 10.2337/dcS15-3022
129. Chu C-S, Tseng P-T, Stubbs B, Chen T-Y, Tang C-H, Li D-J et al. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Scientific Reports. 2018;8(1):5804. DOI: 10.1038/s41598-018-24248-8
130. Wang K-J, Cai X, Tian Y, Wu T, Cao C-X, Bu S-Y. The role of statins in erectile dysfunction: a systematic review and meta-analysis. Asian Journal of Andrology. 2014;16(3):461. DOI: 10.4103/1008-682X.123678
131. Kostis JB, Dobrzynski JM. The Effect of Statins on Erectile Dysfunction: A Meta‐Analysis of Randomized Trials. The Journal of Sexual Medicine. 2014;11(7):1626–35. DOI: 10.1111/jsm.12521
132. Смирнова М.Д., Агеев Ф.Т. Статины – старые мифы и новые факты. РМЖ. 2017;25(20):1421-8
133. Slomski A. Nocebo Effect May Account for Statin Adverse Events. JAMA. 2017;317(24):2476. DOI: 10.1001/jama.2017.7582
134. Pedro-Botet J, Rubiés-Prat J. Statin-associated muscle symptoms: beware of the nocebo effect. The Lancet. 2017;389(10088):2445–6. DOI: 10.1016/S0140-6736(17)31163-7
135. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal. 2018;39(27):2526– 39. DOI: 10.1093/eurheartj/ehy182
Рецензия
Для цитирования:
Зыков М.B. Проблема безопасности липидснижающей терапии. Кардиология. 2019;59(5S):13-26. https://doi.org/10.18087/cardio.2505
For citation:
Zykov M.V. The problem of safety of lipid-lowering therapy. Kardiologiia. 2019;59(5S):13-26. (In Russ.) https://doi.org/10.18087/cardio.2505
Просмотров: 1289
Послать статью по эл. почте 
Оставить комментарий 